Nutex Health, Inc. (NUTX) Stock Forecast
NUTX analyst forecast
as of October 17, 2026- Analyst consensus
- Strong buy 4.80 / 5 from 5 analysts
- Price target
- $288.20 average of analyst targets
- Upside to target
- +54.9% from the latest close
- Next earnings
- November 18, 2026 EPS estimate $5.53
- 52-week range
- $87.01 – $225.00
NUTX analyst ratings
5 analystsNumber of analysts at each rating.
NUTX price target
The average of analyst 12-month price targets compared with the latest close and the 52-week range.
NUTX earnings per share estimates
| Period | Average | Low | High | Year ago | Growth | Analysts |
|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $5.71 | $4.73 | $6.56 | $7.76 | −26.4% | 5 |
| Current fiscal year (2026) | $27.79 | $25.56 | $29.39 | $10.48 | +165.2% | 5 |
| Next fiscal year (2027) | $27.87 | $24.85 | $30.71 | $27.79 | +0.3% | 5 |
Consensus EPS estimates; growth compares the average estimate with the year-ago EPS.
NUTX revenue estimates
| Period | Average | Low | High | Growth | Analysts |
|---|---|---|---|---|---|
| Current quarter (Sep '26) | $215.0M | $211.0M | $216.9M | −19.7% | 5 |
| Current fiscal year (2026) | $872.0M | $866.5M | $883.0M | −0.4% | 5 |
| Next fiscal year (2027) | $964.2M | $937.0M | $1.00B | +10.6% | 5 |
NUTX EPS: reported and forecast
Fiscal years; "E" marks estimates, the line shows the range from the lowest to the highest estimate.
NUTX revenue: reported and forecast
NUTX EPS estimate revisions
| Period | 90 days ago | 60 days ago | 30 days ago | 7 days ago | Now | Change (90 d) | Revisions (30 d) |
|---|---|---|---|---|---|---|---|
| Current quarter (Sep '26) | $5.02 | $5.02 | $5.96 | $5.71 | $5.71 | +13.8% | 5 up · 0 down |
| Current fiscal year (2026) | $21.52 | $21.52 | $28.30 | $27.79 | $27.79 | +29.2% | 5 up · 0 down |
| Next fiscal year (2027) | $23.03 | $23.03 | $28.83 | $27.87 | $27.87 | +21.0% | 5 up · 0 down |
How the consensus EPS estimate changed over the last 90 days, and how many analysts raised or lowered it in the last 30 days.
NUTX earnings surprises
Reported EPS vs the consensus estimate for the last 12 quarters; NUTX beat in 7 of 11.
What analysts expect from NUTX
5 analysts cover Nutex Health; their consensus rating is strong buy (4.80 on a 1–5 scale, where 5 is a strong buy). The average price target is $288.20, 54.9% above the latest close of $186.10. Analysts expect earnings of $27.79 per share for 2026, +165.2% from a year earlier. For 2027 the average estimate is $27.87 per share on revenue of $964.2 million. Nutex Health beat the EPS estimate in 7 of the last 11 quarters.
Related: NUTX income statement, NUTX key metrics, NUTX chart. See the NUTX stock overview for the latest quote and news.
NUTX forecast FAQ
What is Nutex Health's price target?
The average analyst price target for Nutex Health is $288.20, 54.9% above the latest close of $186.10.
Is Nutex Health a buy, hold or sell?
Of 5 analysts covering Nutex Health, 4 rate it a strong buy, 1 a buy, 0 a hold, 0 a sell and 0 a strong sell, a consensus of strong buy. Ratings are opinions, not a recommendation from Quotelinks.
What is Nutex Health's EPS forecast?
Analysts forecast $27.79 per share for 2026 (range $25.56 to $29.39); for 2027 the estimate is $27.87.
What is Nutex Health's revenue forecast?
The average revenue estimate for 2026 is $872.0 million, growth of −0.4%; for 2027 it is $964.2 million.
When does Nutex Health report earnings?
Nutex Health is expected to report results for the quarter ending September 30, 2026 on November 18, 2026; the EPS estimate is $5.53.
Does Nutex Health usually beat earnings estimates?
Nutex Health reported EPS at or above the analyst estimate in 7 of the last 11 quarters.